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Tuberculosis has probably caused more suffering, impoverishment and death than any
disease in human history.  During the 1990s, TB reemerged in the Western Pacific Region
on an alarming scale.  About one third of 8 million cases globally occurred in the Western
Pacific Region alone and led to approximately 1000 deaths per day.  The need for forceful
action was urgent.  The WHO Regional Committee for the Western Pacific, at its fiftieth
session, established the Stop TB Special Project and set the goal of halving the TB prevalence
and mortality by 2010 relative to 2000.  This was followed by the adoption of the Regional
Strategic Plan to Stop TB in the Western Pacific for 2000 to 2005.
Those major efforts resulted in the expansion of the DOTS, an internationally recommended
strategy for TB control, with the number of countries and areas implementing DOTS
increasing from only 17 to all 37 countries and areas of the Region within five years.  The
tide has definitely turned in the regional battle against TB.  The Region is on its way to
halting the spread and reducing the burden of one of the world’s most devastating diseases.
The data for 2005 is expected to show that intermediate TB control targets of detecting
70% of estimated cases, successfully treating 85% of estimated cases and reaching 100% of
the population with DOTS access have already been achieved.  This major accomplishment
is largely due to the commitment of countries and areas in the Region, including their
leaders and the health workers who have dedicated themselves to TB control, as well as
the work of our partners in the Region.
Tremendous momentum has been generated, but the job is not finished.  Building on the
achievements of the first phase of the Stop TB Special Project, the major task over the next
five years will be to achieve the eventual goal of reducing the number of cases and deaths
by one half by 2010 from the 2000 level and contribute to the achievement of the
Millennium Development Goals (MDG).  To do this, we need a solid plan and greater support
for TB control in the Region.
The Strategic Plan to Stop TB in the Western Pacific 2006–2010 has been developed within
the context of the new global Stop TB strategy.  The plan provides a road map with strategies
clearly laid out for achieving the 2010 goal relative to 2000.  Ensuring quality of TB services,
responding to emerging challenges of multidrug-resistant TB and TB-HIV coinfection,
increasing the case detection rate, and intensifying efforts to get both the private and
public health sector involved in TB control are among the priorities included in this plan.
The plan will guide countries and areas in further developing and implementing their
national five-year TB control plans.  The need for bolder action called for by this plan will
require further strengthening of efforts and increased funding at the regional and country
levels.  With the successful implementation of this plan, I am confident that we can achieve
yet another victory against TB in 2010 and bring us closer to our vision of a TB-free world.
Shigeru Omi, MD, Ph.D.
Regional Director
Foreword

1.1 Regional Situation
Following the declaration by the WHO Regional Committee of a
‘tuberculosis crisis’ in the Western Pacific Region in September 1999, a
resolution on tuberculosis prevention and control was adopted to establish
the Special Project to Stop TB1. The Regional Committee in 2000 endorsed
the regional goal of reducing by one-half the TB prevalence and mortality
and set the target for 2010, compared to the level in 20002. As an intermediate
step towards reaching this goal, three regional targets were set to be achieved
by 2005—detecting 70% of estimated TB cases, successfully treating 85% of
these cases and 100% DOTS coverage in the Region.
The first regional strategic plan, which laid out strategies and activities for
2000 to 2005, has been instrumental in achieving this success. The cornerstone
of the first part of the Strategy was based on expanding DOTS to curb the TB
epidemic in the Region. With DOTS expanding rapidly, ensuring high-quality
DOTS implementation became an important concern. Therefore, national TB
programmes were encouraged and assisted in building technical and
managerial capacity to ensure high quality while continuing to expand DOTS
to cover entire populations.
Achieving a 70% case detection rate, an 85% treatment success rate and
regionwide DOTS coverage, or so-called ‘70/85/100’ targets, has been the
major focus of TB control efforts over the last five years.  Tremendous progress
has been made in achieving these intermediate targets.  There has been
remarkable progress in the Region in terms of case detection and DOTS
expansion.  From 2000 through 2004, case detection increased from 45% to
67% and DOTS coverage from 67% and 94%. The treatment success rate has
been exceeding the target of 85% for several years.  With the momentum
generated in recent years, the Region is now poised to achieve the
intermediate targets of 70% case detection and 100% DOTS coverage by 20053.
But achieving the ‘70/85/100’ targets is only an intermediate step towards
achieving the goals set by the Regional Committee for 2010.
Achieving and sustaining these targets over a number of years should
substantially cut disease prevalence and deaths.
Section 1
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‘70/85/100’ targets
is only an
intermediate step
towards achieving
the regional goal
set by the Regional
Committee
by 2010.”
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Estimated Burden
Based on 2004 data, the most recent available, there were an estimated
4 million prevalent cases of TB in the Western Pacific Region (236 per 100 000
population).  Nearly 2 million of those cases were new.  The seven countries
with a high burden of TB (Cambodia, China, the Lao People’s Democratic
Republic, Mongolia, Papua New Guinea, the Philippines and Viet Nam) account
for more than 95% of the total estimated cases in the Region. There were
about 300 000 deaths due to TB in 2003. Published estimates based on
2000–2004 data showed an overall decline of 15% in prevalence and 12% in
mortality, with an annual average rate of decline of 4% and 3%, respectively4.
Case Detection
Increasing case detection was a particular concern in the last five years
because, with the exception of Viet Nam, most countries with a high burden
of TB were detecting less than 40% of their estimated TB cases. Several
strategies were implemented, not only for accelerating DOTS expansion in
public facilities, but also for improving the collaboration of a wider range of
health providers for TB control.  In the last three years, the Region accelerated
DOTS expansion particularly in the countries with a high burden of TB. This
resulted to an improvement in the regional case detection rate and overall
access to TB services.  The acceleration in the Region’s case detection was
largely due to progress in Cambodia, China and the Philippines, which
together accounted for about 92% of the case detection gap. The remarkable
acceleration in China, which doubled its case detection from 30% in 2002 to
65% in 2004, was mainly the result of strengthened political commitment
and increased financing for TB control.
Treatment Success
The overall percentage of registered new TB patients completing anti-TB
treatment has been consistently above the 85% target for the last 10 years.
The Western Pacific Region was the first WHO region to achieve this target.
Five of the seven countries with a high burden of TB (Cambodia, China,
Mongolia, the Philippines and Viet Nam) have been able to reach and sustain
the 85% treatment success target. The two remaining countries with a high
TB burden (the Lao People’s Democratic Republic and Papua New Guinea)
are making strong progress towards the 85% target.  Rapid progress has been
made in the Lao People’s Democratic Republic with treatment success rate
increasing from 60% in 2000 to about 80% in 2003.  In Papua New Guinea,
efforts need to be intensified to expand DOTS and improve the treatment
success rate.
Multidrug-resistant Tuberculosis
Multidrug-resistant tuberculosis (MDR-TB) is posing a substantial threat to TB
control in several countries and areas in the Region. Varying levels of MDR-TB
prevalence were found in almost all settings surveyed in the Western Pacific
Region, ranging from 0.5% in Cambodia to 10.4% in Liaoning Province in
China5.  Data from drug resistance surveillance (DRS) in nine out of 31
provinces in China reveals alarming rates of MDR-TB in more than half of these
provinces. WHO estimates that China has the world’s largest MDR-TB epidemic,
approximately 25% of the world’s cases.
“Varying levels of
MDR-TB were
found in almost all
settings surveyed in
the Western Pacific
Region, ranging
from 0.5% in
Cambodia to
10.4% in Liaoning
Province of China.”
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DOTS-Plusa projects, which are designed to address MDR-TB, are being scaled
up in the Philippines and being initiated in Mongolia. China has developed a
national plan for pilot testing and scaling up DOTS-Plus and has begun
building the necessary technical capacity for implementation. However, the
scope of the threat of MDR-TB in the Region needs to be matched by a
systematic, progressive and quality-assured expansion of DOTS-Plus.  These
initiatives are currently supported by the Green Light Committeeb (GLC)
mechanism. In several more developed countries in the Region, such as the
Republic of Korea, MDR-TB patients are treated with second-line drugs in a
number of specialized centres, which were established outside the GLC
mechanism.
TB-HIV Coinfection
TB associated with HIV infection is a growing threat in the Region, particularly
in areas of China, among specific risk groups in Malaysia, and in Papua New
Guinea and Viet Nam. The prevalence of HIV infection among people with TB
was 13% in Cambodia and 4% in Viet Nam, but there are specific areas or
groups within those countries where TB-HIV prevalence is comparable to the
high rates seen in sub-Saharan Africa5. In most countries and areas in the
Region, the level of TB-HIV coinfection is not determined because surveillance
has not yet been established.
To address the emerging threat of TB-HIV coinfection, a collaborative approach
between the national TB and HIV/AIDS programmes was advocated. In 2004,
the Region published Tuberculosis and HIV: A framework to address TB-HIV
coinfection in the Western Pacific Region,6 that provides guidance to countries
and areas to establish collaborative activities between their national TB
programme and the national AIDS programme. Collaboration between HIV
and TB programmes has been established in Cambodia and pilots have been
set up in Viet Nam. In China, a national framework to address TB-HIV has been
developed. However, access to antiretroviral treatment by HIV-infected TB
patients is still very much limited, as HIV/AIDS programmes have not fully
embraced HIV-TB as a key component of their strategy. This will likely change
because of the increasing recognition that addressing TB-HIV will contribute
to reducing mortality among HIV-infected persons. The joint WHO and UNAIDS
approach to “universal access” may improve access to antiretroviral therapy
overall, including for HIV-infected TB patients7.
Access of Poor and Vulnerable Populations
TB is a disease of poverty that thrives on deprivation and inequality. Within
countries, the distribution of TB is higher among the poor than among non-
poor. For example, in the Philippines, where poverty prevalence is still close
to 40%, the prevalence rate of sputum smear-positive TB was found to be 1.6
times higher in urban poor communities than in urban non-poor
communities8. Of the seven countries with a high burden of TB, five
(Cambodia, the Lao People’s Democratic Republic, Mongolia, Papua New
Guinea and Viet Nam) are low-income countries.  China and the Philippines
are considered to be low-to middle-income countries.
a DOTS-Plus -  a term that refers to piloting of the management of drug resistant TB within the
context of basic DOTS programmes. More recently, DOTS-Plus is referred to as programmatic
management of MDR-TB.
b Green Light Committee - a global mechanism that aims to ensure access to cheaper and quality-
assured second-line drugs, to assist countries develop and  implement high quality DOTS-Plus
projects, and to develop evidence-based policies related to DOTS-Plus.
“TB associated
with HIV is a
growing threat
facing the Region,
particularly in
Cambodia, areas of
China, Malaysia,
Papua New Guinea
and Viet Nam.”
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TB among vulnerable populations is a special concern in the Region,
particularly where access to health services is limited (e.g. migrant populations
within China, prisoners in Mongolia, and geographically remote populations
in Viet Nam).  Other vulnerable populations include homeless people (e.g.
Japan and Mongolia) and drug users (e.g. China, Malaysia and Viet Nam).  Most
of these vulnerable groups are at increased risk for contracting TB because
they are likely to find themselves in situations characterized by poor sanitation,
overcrowded housing, disruption of social networks, discrimination and
poverty18.  In some areas, the increasing number and proportion of TB cases
reported among these groups have affected regional or national trends in
the TB case notification.  In China, for example, where there is unprecedented
migration from rural to urban areas, some cities are reporting substantial
increases in the notification of TB cases and in the proportion of TB cases
among migrant populations (e.g. proportion of reported TB cases in Beijing
among migrants increased from 10% in 1993 to 37% in 2005)9.  Detecting
and curing TB in these groups pose special challenges because of a range of
factors, including increased mobility, legal status (e.g. illegal migrants) and
access to health facilities.
1.2 The Rationale for a Strategic Plan
for 2006–2010
In 2000, the Regional Committee for the Western Pacific endorsed the impact
targets of a 50% reduction in TB prevalence and mortality within 10 years.
The Region has since achieved substantial progress in terms of expanding
DOTS regionwide, detecting 70% of the cases and exceeding 85% treatment
success rate. But the job is not finished. If the Region is to achieve the impact
targets by 2010, it needs to accelerate the rate of decline in prevalence and
mortality from the current 3% to about 8% per year over the next five years
(see figure 1)10.  This means that the Region faces a tougher challenge for
achieving the 2010 targets, and needs to further strengthen efforts and take
a much bolder approach in TB control.
FIGURE 1. TRENDS IN TB PREVALENCE AND MORTALITY RATES OF TB PER 100 000
POPULATION IN WPR, 1990–2005
“A continued level of
a 70% case detection
rate will not be
sufficient to achieve
the regional goal by
2010 .”
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A strategy is,  therefore,  needed to address what issues fur ther
constrain declines in TB prevalence and mortality. There are three
major areas of concern: (1) the current level of case detection will not
be sufficient to achieve the impact targets; (2) MDR-TB and TB-HIV
coinfection threaten to slow down the decline in prevalence or
mortality ;  and (3) conventional DOTS service delivery does not
guarantee equitable access to TB services.
The first area of concern is increasing case detection beyond 70%. A
continued level of 70% case detection rate will not be sufficient to
achieve the impact targets by 201010 .   Mathematical modelling
projections suggest that an increase of case detection beyond 70% is
needed over the next five years, but this will require tremendous effort.
It will entail enhancing laboratory capacity with specific attention to
implementing external  qual ity assessment,  as well  as careful ly
considering the Region’s capacity to benefit from new tools for
diagnosis .  Sustaining already establ ished mechanisms such as
effective monitoring and supervision of DOTS implementation also
will be important.
The second area of concern is the threat posed by MDR-TB and TB-HIV
coinfection in reversing the gains in TB control.  The Region needs to
control the spread of MDR-TB. The MDR-TB epidemic threatens to slow
the decline in prevalence and mortality because it leads to more
chronic cases and increased mortality.  HIV-related TB is a serious threat
due to its impact on TB case fatality, which is about four times higher
than among HIV-negative TB patients, even under well-performing TB
programmes11.
The third area of concern is ensuring that all TB patients have access
to TB services.  DOTS delivered through the conventional National TB
Programme (NTP) service delivery mechanisms does not ensure that
patients who seek services in general hospitals and from private
providers and those in special situations, such as the homeless, drug
users, migrants and prisoners, have access to high-quality TB services.
People in these situations may not receive good quality DOTS services
because these are not made available to them or they simply do not
seek services through conventional health delivery mechanisms.
Scaling up the involvement of a wide range of non-NTP health
providers for TB control and developing and implementing special
activit ies for poor and vulnerable populations wil l  help ensure
equitable access to these services.
Therefore, to reach the impact targets of reducing the TB prevalence
and mortality by one half by 2010, The Strategic Plan to Stop TB in the
Western Pacific 2006–2010 emphasizes, not only increased case
detection but also control of the MDR-TB and TB-HIV coinfection and
equitable access to high-quality TB services for all patients. The
Strategic Plan provides a reference for actions to address these
priorities. It outlines strategies that will translate into practice at the
regional and country levels the new Stop TB Strategy (see Box 1) that
has been developed at the global level to help achieve the Millennium
Development Goals (MDGs) for TB12.
"To reduce by the TB
prevalence and
mortality by
one half by 2010, the
Region should go
beyond 70% case
detection rate,
address the threat of
MDR-TB and
TB-HIV coinfection
and ensure that all
TB patients have
equitable access to
high-quality TB
services."
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Vision A world free of TB
Goal • To reduce dramatically the global burden of TB by 2015
in line with the Millennium Development Goals and the
Stop TB Partnership targets
Objectives • To achieve universal access to high-quality diagnosis and
patient-centred treatment
• To reduce the suffering and socioeconomic burden
associated with TB
• To protect poor and vulnerable populations from TB,
TB-HIV, and MDR-TB
• To support development of new tools and enable their
timely and effective use
Components of the Strategy and implementation approaches
1. Pursue high-quality DOTS expansion and enhancement
a. Political commitment with increased and sustained financing
b. Case detection through quality-assured bacteriology
c. Standardized treatment with supervision and patient support
d. An effective drug supply and management system
e. Monitoring and evaluation system and impact measurement
2. Address TB-HIV, MDR-TB and other challenges
a. Implement collaborative TB-HIV activities
b. Prevent and control MDR-TB
c. Address prisoners, refugees and other high-risk groups, and special
situations
3. Contribute to health system strengthening
a.     Actively participate in efforts to improve system-wide policy, human
resources, financing, management,  service delivery and information
systems
b. Share innovations that strengthen systems, including the Practical
Approach to Lung Health (PAL)
c. Adapt innovations from other fields
4. Engage all care providers
a. Public-Public and Public-Private Mix (PPM) approaches
b. International Standards for Tuberculosis Care (ISTC)
5. Empower people with TB, and communities
a. Advocacy, communications and social mobilization
b. Community participation in TB care
c. Patients' Charter for Tuberculosis Care
6. Enable and promote research
a. Programme-based operational research
b. Research to develop new diagnostics, drugs, and vaccines
BOX 1.  THE STOP TB STRATEGY
Section 2
The Framework
of the Strategic Plan
The framework of the Strategic Plan is based on a four-level hierarchical
structure: Vision, Goal, Objectives, and Expected Results. Figure 2 provides, at
a glance, the framework with all the important components of the Strategic
Plan (see next page).  It shows the hierarchy of desired outcomes and the
specific targets and indicators that have been designed for each of the
objectives and expected results.
Vision and Goal
The vision as laid out in the Strategic Plan is to eliminate TB as a public
health problem in the Region. The definition of elimination is an incidence
rate of less than one TB case per one million population12, 13.
The goal is to reduce the prevalence and mortality from all forms of TB by
one half by 2010 relative to 2000, contributing to the achievement of the
Millennium Development Goals (MDGs). This goal is consistent with the
targets set by the WHO Regional Committee in 2000, which was a response
to the TB crisis in the Region and the new Stop TB Strategy developed at
the global level to achieve the MDGs relevant to TB.
Millennium Development Goal 6
Combat HIV/AIDS, malaria and other diseases
Target 8
To have halted by 2015 and begun to reverse the incidence of malaria and
other major diseases
BOX 2.  MILLENNIUM DEVELOPMENT GOAL AND TARGET RELEVANT TO TB
FIGURE 2
The Framework of the Strategic Plan
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2.1 Strategic Objectives and Expected Results
To achieve the goal, the Region needs to meet the following three strategic
objectives:
Strategic Objective 1
To sustain and optimize the quality of DOTS
and go beyond the ‘70/85’ targets
Strategic Objective 2
To ensure equitable access to high-quality TB care
for all people with TB
Strategic Objective 3
To adapt DOTS to respond to MDR-TB and the TB-HIV
coinfection
Indicators to measure progress towards achieving the objectives and
corresponding targets have been identified for each of the Strategic Plan’s
objectives. Four core regional targets will be monitored closely at the regional
level and serve as markers of progress towards achieving the impact targets.
Under each of the three objectives, expected results that represent the
building blocks for achieving the objectives should be adapted according to
the countries’ needs.  The specific activities should be formulated in the
national TB control plans and the WHO action plans.
Strategic Objective 1
To sustain and optimize the quality of DOTS and go beyond the
‘70/85’ targets
The Region has made substantial progress since the first regional Strategic
Plan was endorsed by the WHO Regional Committee in 2000. The
implementation of DOTS has accelerated with the number of countries and
areas implementing DOTS doubling to 34 by 2004. This has resulted in an
increase in the population of the Region with access to DOTS from 67% in
2000 to 94% in 2004. Similar remarkable progress has been achieved in
improving the case detection rate from around 40% in 2000 to 67% in 2004.
In 2005, the momentum was sustained. The 2005 data are expected to show
that the targets of 100% DOTS coverage and 70% case detection rate have
been met.
However, the rapid scale-up of DOTS coverage has resulted in challenges,
including the high demand in some countries and areas on their limited health
systems capacity, human resources and health infrastructure. This has
compromised the quality of DOTS implementation in certain areas, including
the quality of laboratory diagnosis and directly observed therapy, limited
training and supervision at peripheral levels, inefficiencies in drug
management in some areas, and concerns of accuracy and reliability of
information systems for reporting and referral. Poor quality of DOTS
implementation in some areas undermines the gains from DOTS expansion
(e.g. through the creation of more drug resistance) and could hinder a further
“The rapid scale-up
of DOTS coverage
has resulted in
challenges, including
the high demand on
the countries’ limited
health systems
capacity, human
resource, and health
infrastructure.”
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increase in case detection and improvement in case management. As
emphasized in Section 1, sustaining a high level of case detection and cure
rates in the next five years is critical to reducing the TB prevalence and
mortality.
This will mean implementing more systematic approaches to increasing
human resource competence and availability, further investing in
strengthening laboratory capacity and quality in the Region, especially for
sputum smear microscopy, improving drug management, programme
supervision, and recording and reporting.
TARGETS
A. Beyond 70% Case Detection Rate
Definition: Of the estimated incident TB sputum smear-positive cases in the
Region, more than 70% are detected.
The mathematical modelling projections that guided the development of
the regional Strategic Plan for 2006–2010 suggest that the average annual
rate of decline in TB prevalence and mortality would have to fall further by
more than twice the current level over the next five years to reach the impact
targets by 2010 (see Figure 3 and Figure 4).  To do this, the case detection rate
must be increased to at least 80% from 2006 onward10. With this level
sustained, the TB prevalence and mortality would be reduced by more than
50% in 2010, thus enabling the Region to reach the targets set by the WHO
Regional Committee in 2000.
FIGURE 3. IMPACT OF ‘BEYOND 70%’ CASE DETECTION RATE ON DECLINE IN TB PREVALENCE
“To reach the 2010
impact targets, the
Region must
increase and sustain
case detection rate
to at least 80% from
2006.”
FIGURE 4. IMPACT OF ‘BEYOND 70%’ CASE DETECTION RATE ON DECLINE IN TB MORTALITY
Resource Needs and Gaps
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Enormous efforts made by countries and areas were necessary to reach the
70% case detection rate.  Increasing and sustaining the case detection rate to
at least 80% will require intensified efforts.  The appropriate strategies will
vary among countries, but implementation of high-quality DOTS will be critical
to further increase and sustain case detection beyond 70%. These strategies
include enhancing diagnostic capacity, including the implementation of the
quality assurance programmes for sputum smear microscopy. The Region
should capitalize on the opportunity to explore the potential for enhancing
or scaling up existing methods to improve further TB diagnosis and piloting
new technologies to improve TB diagnosis as they become available.
B. Beyond 85% Cure Rate
Definition: In a cohort of new TB patients with a positive sputum smear registered
in a given year, more than 85% are confirmed as cured.
The Region has been able to sustain a cure rate exceeding the 85% target for
several years. Cure is defined as a patient with previously positive sputum
smear becoming smear-negative in the last month of treatment and on at
least one previous occasion14.  Sustaining a high cure rate is as crucial as
increased case detection to achieve the Region’s impact targets on TB
prevalence and mortality. Achieving high cure rates under an environment
of high case detection rate cuts TB transmission, averts deaths and prevents
the occurrence of MDR-TB.
Cure is not only a measure of success for the individual, but a measure of the
quality of the delivery of the TB control programme. Cure does not only
depend on the efficacy of anti-TB drugs, but is also affected by a number of
programmatic factors15, 16. These factors include: (1) accessibility of treatment
services; (2) awareness of TB in the community; (3) uninterrupted supply of
effective TB drugs; and, (4) treatment adherence through DOTS.
Achieving this target, therefore, will involve addressing programmatic factors,
which are essentially related to ensuring high-quality DOTS implementation.
Strategic Objective 2
To ensure equitable access to high-quality TB care for all
people with TB
Although the 2005 target of reaching 100% population coverage with DOTS
has been achieved, a substantial proportion of persons in covered populations
still do not have adequate access to DOTS services. These groups include
patients from non-NTP facilities, the poor, at-risk groups and persons in special
situations, including slum dwellers, homeless people, migrants, people in
prisons and rehabilitation centres, and injecting drug users. Providing access
means being able to remove or alleviate the barriers that TB patients face in
accessing high-quality TB services. For example, for the urban poor, although
TB services may be available, these services are either substandard or the high
indirect or direct costs, including transportation, service co-payments, and
social and cultural impediments are beyond their reach. For some groups, such
as homeless people and migrants, services are not effectively available. With
TB disproportionately higher in these groups, failure to provide them with
high-quality and effective free services is a serious threat to reversing the gains
made in reducing TB prevalence and mortality.
“Adoption of PPMD
that involved private
health providers
showed the potential
to increase case
detection by as
much as 20% and to
significantly improve
TB case
management.”
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Addressing the needs of the poor, at-risk groups and people in special
situations, such as prisoners and people in rehabilitation centres, should be
carefully planned to meet their special needs.  Special initiatives or activities
for these groups should be built into the regular DOTS programme to ensure
that all TB patients receive high-quality TB services.  One strategy to provide
wider access to high-quality and effective services is the Public-Private or
Public-Public Mix DOTS (PPMD), which is an approach that encourages all
non-NTP providers to adopt the DOTS strategy. This approach has the potential
to reach TB patients who otherwise do not access public TB facilities. In this
manner, PPMD contributes to increased case detection. As a complementary
strategy to PPMD, the adoption of the International Standards of  TB Care,
which is scheduled to be published by WHO and several international partners
in TB control in 2006, will be useful to establish high standards for the quality
of care for all TB patients, especially among private sector providers17.
Special attention is needed to address the needs of migrant populations,
particularly in China where huge numbers of people are moving from rural
to urban areas.  The high mobility of these populations, especially transient
migratory workers, poses a challenge to diagnosis and treatment of TB among
these groups.  Addressing the needs of TB suspects and patients who regularly
or occasionally, cross borders between countries is also needed. A good
example is the frequent movement of migrant workers from one Pacific island
country or area to another, and between Pacific island countries and areas
and Australia or New Zealand. Cross-border issues are also important for
countries in the Mekong region where TB suspects or patients visit health
facilities on either side of the border.  Coordination of diagnosis and treatment
(e.g. differences in treatment regimens between countries and between health
facilities) poses a real challenge for the respective national TB control
programme.
To promote equitable access and the utilization of TB services, strategies to
influence both the supply and demand side of services need to be
implemented.  For example, while improving the quality of services, country
activities to promote participation of communities and health-seeking
behaviour that would result in early case detection are important. Advocacy
activities to influence policies that promote equitable access to services by
all TB patients at all levels also will be crucial. Moreover, effective approaches
that address the special needs and situations of the poor, migrants and other
vulnerable groups need to be developed, demonstrated and documented.
TARGET
At least 90% of registered facilitiesc are referring or providing DOTS
services
Definition: Of the total health facilities with potential to be involved in TB control,
90% are providing DOTS services, or are referring to facilities providing
DOTS services.
There are several ways to measure progress in improving access to DOTS
services by all patients. One of the most relevant and practical is to measure
the Region’s progress in increasing the number and diversity of health facilities
involved in TB control, either by referral or actually providing DOTS services.
c Definition of ‘facilities‘ includes private, general hospitals, and other country-specific non-NTP health
providers that should be in involved in TB control.
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In many countries and areas in the Region, people suspected of having TB
and TB patients currently seek health care from many different providers and
facilities outside the network of the NTP. These include private clinics, non-
NTP general hospitals, workplace clinics, pharmacies and traditional modes
of health delivery. Enabling these facilities to refer or provide services through
the PPMD approach greatly expands the network through which high-quality
DOTS services are provided. Experiences with PPMD show the potential to
increase case detection by much as 20% and to significantly improve case
management17. If such results can be replicated across the Region, a
substantial contribution to the reduction in TB prevalence and mortality can
be made.
Strategic Objective 3
To adapt DOTS to respond to MDR-TB and TB-HIV coinfection
Increased case detection to 80% in itself will not be enough to achieve
the 2010 impact targets because of the threat of a MDR-TB epidemic
(particularly in several provinces in China and in the Philippines and
Mongolia) and the growing concern about TB-HIV coinfection.  MDR-TB
and TB-HIV coinfection present two major threats that could undermine
the gains in TB control and hinder the achievement of the regional goal
in 2010.
MDR-TB has been an ever-present threat in the Region, but the problem
is aggravated by inadequate treatment of patients with MDR-TB and the
resultant amplification of drug resistance due to the misuse of second-
line drugs in some parts of the Region. MDR-TB is a threat to TB control in
the Region because it increases the number of chronic cases and the
subsequent transmission of primary MDR-TB. The case fatality rate among
MDR-TB cases is about 10 times higher than among non-MDR-TB cases
and approaches the fatality of untreated TB21.  Thus, MDR-TB has a
significant impact on both TB prevalence and mortality.
There is increasing evidence that the management of MDR-TB under
programmatic conditions, although rather complex, is feasible. DOTS-Plus,
a programme designed to address MDR-TB, needs to be initiated or scaled
up in countries and areas where MDR-TB is an increasing problem.  In the
long run, the most important impact of DOTS-Plus will be to curb the
MDR-TB epidemic.  If 10% of the MDR-TB cases detected under DOTS
programmes would also be covered under DOTS-Plus, a substantial
number of MDR-TB cases could be averted in the coming decade, creating
an impact both on incidence and prevalence of MDR-TB.  Progressive
DOTS-Plus implementation may prevent 2% of cumulative incident MDR-
TB cases and 16% prevalent MDR-TB cases by 201510. (see Figure 5 and
Figure 6)
In several parts of the Region, HIV prevalence is threatening to reverse
gains in TB control.  HIV infection fuels the TB epidemic, and HIV infection
and TB form a deadly combination. TB case fatality among patients with
HIV is about four times higher than among HIV-negative TB patients even
under a well-functioning TB programme11.  Hence, HIV infection reduces
the overall cure rate because of increased mortality. Although some
progress have been made to address the threat of TB-HIV coinfection in
some areas in the Region, particularly Cambodia, it has not been dealt
“Progressive
implementation of
DOTS-Plus in the
next few years has a
significant impact
on the overall TB
mortality over the
long term.”
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“The first crucial
step is to build an
effective
collaboration
between the two
programmes,
followed by the
initiation and
scaling up of
collaborative
activities.”
with systematically and measures taken have not been sufficient to
effectively respond to the seriousness of the threat.
To reduce TB mortality among patients coinfected with TB and HIV,
patients need to be identified early and provided with antiretroviral
therapy if eligible.  However, in the absence of effective collaboration
between TB and HIV programmes, this is unlikely to happen.  The first
crucial step is to build an effective collaboration between the two
programmes (e.g.  TB-HIV task forces or TB-HIV committees), followed by
the initiation and scaling up of collaborative activities according to the
level of TB-HIV prevalence. This entails developing a clear and documented
joint plan and mechanism for collaboration.
In the next several years, it will be important for China, Malaysia,    Papua
New Guinea and Viet Nam to implement collaborative TB-HIV activities
through a formally established mechanism and plan. The need for TB-HIV
collaborative activities in the Lao People’s Democratic Republic needs to
be assessed, and a joint plan developed based on the needs.  Cambodia
will need to scale-up its TB-HIV activities. All countries, particularly those
with a high burden of TB and those with intermediate burden of TB, should
monitor the TB-HIV situation by implementing joint surveillance activities.
FIGURE 5. IMPACT OF DOTS-PLUS ON MDR-TB PREVALENCE RATES IN THE GENERAL
POPULATION
FIGURE 6. IMPACT OF DOTS-PLUS ON THE PROPORTION OF MDR-TB AMONG
PREVALENT TB CASES
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TARGETS
A. At least 90% of MDR-TB cases identified by drug susceptibility
testing (DST) provided with second-line anti-TB drugs
Definition: Of the MDR-TB patients identified by DST under the DOTS-Plus
programme, at least 90% are provided with quality-assured second-
line treatmentd.
The mathematical modelling projections suggest that MDR-TB needs to be
controlled to reach the TB targets by 2010.  An increase of coverage of second-
line treatment delivered effectively through DOTS-Plus contributes to reducing
the TB prevalence and mortality.  Without proper treatment, MDR-TB leads to
more chronic cases resulting in the transmission of primary MDR-TB and
increased case fatalities among MDR-TB patients. Therefore, increasing access
to quality-assured second-line treatment through a DOTS-Plus programme is
an essential intervention to address the threat of MDR-TB.
The above core indicator/target measures the extent to which second-line
drugs are made continuously accessible to identified MDR-TB patients.  Other
indicators will be measured in order to determine the coverage of DOTS-Plus.
For example, the percentage of re-treatment cases with DST can be used to
determine the extent to which DOTS-Plus services are made available to
patients who are primarily at risk for MDR-TB.
B. At least 90% Antiretroviral Therapy (ART) coverage of eligible
patients with TB-HIV coinfection
Definition: Of the TB patients with HIV coinfection found to be eligible for ART
through collaborative TB-HIV programmes, at least 90% are provided
with ART.
Antiretroviral therapy is an essential part of the intervention to reduce mortality
related to TB-HIV coinfection. The Region needs to make good progress over
the next five years to improve the coverage of ART among TB patients in
order reduce mortality, especially in areas with high prevalence of TB-HIV
coinfection.  In countries and areas with national HIV prevalence of more than
1% or with an HIV prevalence rate of at least 5% among TB patients, TB and
HIV programmes should work together to regularly screen TB patients for HIV
infection, and similarly try to identify people with HIV/AIDS among TB patients6.
Patients who are identified with TB-HIV coinfection through this mechanism
and are found to be eligiblee for antiretroviral therapy should be provided
with it.  TB programmes will be relying on effective collaboration with HIV
programmes to improve access to ART for TB patients.  Ideally, all eligible TB
patients should receive ART, but the limitations as to the pace of expansion
of ART in the Region may constrain the achievement of 100% coverage.
d The denominator could vary between countries with high burden of TB (HBC) and countries and
areas with intermediate burden of TB (IBC). For HBC the denominator could be restricted to MDR-
TB patients identified in DOTS-Plus programmes; for IBC, it could include those identified in the
public and private sector collaborating with NTP.
e The WHO guideline entitled, Scaling Up Antiretroviral Therapy in Resource-limited Settings: Treatment
Guidelines For A Public Health Approach, defines eligibility and includes the timing of ART initiation
based on CD4 cell counts.  Recommendations are also made when CD4 testing is not available.
Four core targets have been drawn from the objectives of the Strategic Plan. These represent
the strategic areas in which progress is critical to achieve the impact targets of a 50%
reduction in TB prevalence and mortality by 2010 relative to 2000, and which will be
monitored closely over the period of the plan. These new process targets represent a strategic
shift from the ‘70/85/100’ targets of the first Regional Strategic Plan for 2000-2005 to the
‘50/50’ targets of the second regional strategic plan for 2006–2010. The core targets provide
bold yet measurable focus for the Region towards achieving the eventual goal for TB control.
CORE TARGET 1: Beyond 70% case detection
Definition: Of the estimated incident TB sputum smear positive cases in the Region, greater than
70% are detected.
Mathematical modelling projections indicate that maintaining the regional case
detection rate at 70% will not be sufficient to reach the impact targets to reduce the
TB prevalence and mortality by 2010.  The case detection rate should be increased to
over 80% starting 2006 and be sustained until 2010 to achieve the impact targets by
2010.  Increasing case detection rate to this level will be the single most important
contributing factor to accelerating the average annual rate of decline in prevalence
and mortality.
CORE TARGET 2: At least 90% PPMD coverage
Definition: Of the total health facilities with potential to be involved in TB control, 90% are
providing DOTS services, or are referring to facilities providing DOTS services.
Many TB suspects and patients access services from a range of providers outside the
NTP network. Increasing the involvement of non-NTP health providers and facilities
in providing or referring to DOTS services through the PPMD approach widens the
base through which high quality TB services can be delivered to all TB suspects and
patients.
CORE TARGET 3: At least 90% DOTS-Plus coverage
Definition: Of the MDR-TB patients identified by DST under the DOTS-Plus programme, at least
90% are provided with quality-assured second-line treatment.
Increasing coverage of DOTS-plus programmes is essential to address the threat that
MDR-TB poses to slowing down the decline in prevalence and mortality, thus
preventing the Region from achieving the impact targets by 2010. DOTS-Plus increases
access to quality-assured second-line drugs and provides a mechanism to deliver the
complex treatments for MDR-TB patients, including ensuring adherence to treatment.
CORE TARGET 4: At least 90% ART coverage
Definition: Of the TB patients with HIV infection found to be eligible for ART through
collaborative TB-HIV programmes, at least 90% of them are provided with
antiretroviral treatment.
Mortality among TB patients with HIV/AIDS is much higher than among TB patients
without HIV/AIDS. Ensuring access and promoting adherence to ART is perhaps the
most essential intervention to reduce mortality among patients with TB-HIV co-
infection. However, access of TB patients to ART has been very limited until recently.
Achieving a high coverage of TB-HIV collaborative activities, especially in areas with
high TB-HIV prevalence will be essential.
BOX 3. CORE REGIONAL TARGETS BY 2010
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2.2 Expected Results
The following chapter presents a series of expected results related to the three
strategic objectives. Indicators and targets have been created for each
expected result to monitor progress. The expected results are building blocks
towards achieving the objectives. They describe the specific desired results
of actions needed in order to achieve the objectives.  However, the list of
expected results is not exhaustive. The context and level of importance of
some of the intermediate results required to achieve the objectives vary
among countries and areas. The expected results with its proposed indicators
and targets are subject to adaptation as per country needs.  Specific activities
that will be implemented to achieve these expected results are to be
formulated in the national TB control plans and the WHO action plans.
Strategic Objective 1
To sustain and optimize the quality of DOTS and go beyond the
‘70/85’ targets
The following table shows the three expected results under this objective
and their corresponding indicators and targets, which are discussed in detail
below.
Expected Result 1.1
Country capacity and quality of diagnosis for TB assured
In the absence of new and more practical TB diagnostic tests, high-quality
sputum smear microscopy remains the recommended method for TB case
detection. To ensure access to high-quality sputum smear microscopy services,
a wide network of properly equipped laboratories with trained personnel and
the implementation of a quality assurance system are necessary.  Many
countries and areas in the Region have gradually expanded their quality
assurance activities in the last two years, but not all aspects of a good quality
assurance programme have been implemented. Based on unpublished data
reported to WHO, some countries with more than 10% of laboratories showing
poor performance have not taken sufficient corrective action.
It is crucial that countries and areas intensify their efforts to implement
quality assurance and pursue improvement of laboratory network capacity
to respond to the increasing demands of the expanding TB services in
the next five years.  Increasing case detection and addressing the emerging
threats of MDR-TB and TB-HIV put increased pressure on existing laboratory
“To ensure access to
high-quality sputum
smear microscopy
services, a wide
network of properly
equipped
laboratories with
trained personnel
and the
implementation of
quality assurance
system are
necessary.”
DESCRIPTION INDICATORS AND TARGETS
Expected Result 1.1
Expected Result 1.2
Expected Result 1.3
Country capacity and quality of
diagnosis for TB assured
Uninterrupted supply of quality-
assured anti-TB drugs at all DOTS
units
Enhanced case management for
all registered TB cases, including
smear-negative TB
At least 90% laboratory units with
satisfactory performance
100% of treatment units with
uninterrupted supply of drugs in a
given year
All HBC have developed guidelines for
diagnosis and treatment of smear
negative TB, e.g. children
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capacity.  In high MDR-TB and TB-HIV prevalence settings, culture and DST
can be an important diagnostic tool and should be introduced in a phased
manner at appropriate referral levels of the health system.  For the use of
culture for routine diagnosis, many countries in the Region face resource
constraints and may not meet the required conditions for the rational use
of culture.  National guidelines need to be developed on the use of culture
and DST, including the potential use of diagnostic committees to
contribute to ensuring the accuracy of diagnosis.
Expected Result 1.2
Uninterrupted supply of quality-assured anti-TB drugs at all DOTS units
An uninterrupted supply of high-quality, affordable, first-line anti-TB drugs
is critical to the effective implementation of DOTS. Increasingly, countries
provide adequate budget support to procure these drugs. In addition,
the supply of quality-assured and affordable first-line TB drugs through
the Global Drug Facility (GDF) by means of direct procurement or grant
assistance has been used in several countries in the Region. To ensure
maximum benefit of the available anti-TB drugs, countries need to
introduce and sustain an effective drug management system.
For second-line drugs, the Green Light Committee (GLC) provides a
rigorous mechanism through which quality-assured, second-line drugs
can be made available in countries to treat MDR-TB in DOTS-Plus
programmes.
Expected Result 1.3
Enhanced case management for all registered TB cases, including smear-
negative TB
The countries and areas in the Region continue to report almost the same
number of smear-negative TB and extra-pulmonary TB as smear-positive
TB cases.  In 2004, about 481 000 smear-negative and extra-pulmonary TB
cases were reported compared to about 580 000 new smear-positive cases.
From a public health point of view, priority in TB control is given to the
diagnosis and treatment of smear-positive TB only as they represent the
highly infectious TB cases.  Smear-negative pulmonary TB and to a lesser
extent, extra-pulmonary TB, contributes significantly to the impact of TB
on morbidity and mortality21.
Among people with HIV, smear-negative TB and extra-pulmonary TB are
more common and more difficult to diagnose.  TB in children is frequently
not recognized and can therefore contribute to a higher mortality.  To
improve the diagnosis and management of smear-negative TB, extra-
pulmonary TB and TB among children, evidence-based diagnostic
algorithms, CXR and sputum cultures may play a role.   Specif ic
recommendations on the use of these tools were made at the global
level22. The countries and areas in the Region may consider the application
of these recommendations after careful assessment of the situation.
Developing relevant policies, guidelines and practical activities to
strengthen the management of smear-negative and extra-pulmonary TB
will entail wide consultations, and should be supported by operational
research.
The Framework of the Strategic Plan
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Strategic Objective 2
To ensure equitable access to high-quality TB care for all people
with TB
The following shows the four expected results under this objective and their
corresponding indicators and targets, which are discussed below in more
detail.
Expected Result 2.1
Improved TB case management in non-NTP TB facilities
Currently, the overall cure rate in the non-NTP facilities, including the
private sector, is much lower than in NTP facilities. Furthermore, the quality
of diagnosis and treatment in non-NTP facilities in general is not
standardized and not quality assured. Poor TB case management
contributes to unnecessary suffering for patients, diagnostic delays, the
continuous spread of TB, high health care costs for patients and society,
and the development of MDR-TB.
To address these issues, PPM DOTS approach is increasingly advocated in
the Region.  This approach targets a wide range of private and non-NTP
public health providers who are dealing with TB. However, improved efforts
are needed to strengthen the implementation of technical capacity and
the coordination of PPM DOTS at the country level, since there are still
large numbers of public and private health care providers that have not
adopted the DOTS strategy.
Expected Result 2.2
Adoption of the International Standards of Tuberculosis Care (ISTC) and the
Patients’ Charter for Tuberculosis Care (PCTC)
The adoption of the recently published International Standards of Tuberculosis
Care (ISTC) complements the implementation of the PPM DOTS approach to
ensure the quality of TB service delivery.  The ISTC describes a widely accepted
standard of TB care that all practitioners, public or private, should follow in
dealing with patients who have, or are suspected of having, TB16. The ISTC
DESCRIPTION INDICATORS AND TARGETS
Expected Result 2.1
Expected Result 2.2
Expected Result 2.3
Improved TB case management
in non-NTP TB facilities
Adoption of the International
Standards of Tuberculosis Care
(ISTC) and the Patients' Charter
for Tuberculosis Care (PCTC)
Increased utilization of TB
services by poor and vulnerable
populations
At least 85% cure rate of TB cases
managed by non-NTP facilities
All countries and areas have
introduced the ISTC and the PCTC
At least 10% of cases notified under
pro-poor TB initiatives (or a specific
underser ved population, e.g.
migrant)
All HBC are implementing ACSM
strategies for TB control on a national
scale
Expected Result 2.4
Country-driven advocacy,
communications and social
mobilization (ACSM) strategies
developed and implemented
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presents a set of principles and actions, covering three categories of activities
including diagnosis, treatment and the public health responsibilities of all
providers.
The Patients’ Charter for Tuberculosis Control was developed in tandem with
the ISTC to promote a patient-centered approach to tuberculosis care23. It
outlines the rights and responsibilities of people with tuberculosis and sets
out ways in which patients, community, health providers and governments
can work as partners in improving tuberculosis care.
It is intended that both the ISTC and the Patients’ Charter for Tuberculosis
Care will be adopted together. In countries and areas where the ISTC will be
adopted, it is expected that the engagement of all care providers in delivering
high-quality care for TB patients of all ages will be facilitated through the
development and implementation of guidelines and policies based on these
standards.  It is envisaged that the ISTC will be endorsed and promoted by all
countries and areas, especially among professional organizations and other
health care entities.  The adoption of the Patients’ Charter is expected to lead
to involvement of patients in their care and to foster mutual interaction and
positive partnership between patients and health providers.
Expected Result 2.3
Increased utilization of TB services by the poor and vulnerable populations
There are three main reasons for TB programmes to focus on increasing access
to DOTS by the poor, at-risk groups and people in special situations who are
more vulnerable to TB. Firstly, TB among these groups may comprise many of
the undetected cases.  Therefore, it is expected that strategies to increase
access to DOTS by the poor and vulnerable populations will contribute to
increasing case detection. For example, there is sufficient evidence of low TB
case detection and low treatment success rates in the large migrant or so-
called floating populations in China (estimated at more than 150 million
people). Therefore, there is an urgent need to control TB within this group,
particularly as internal migration continues to increase. Secondly, strategies
to improve access are necessary to resolve inequity in the burden of TB and
access to TB control. Thirdly, reaching the poor, groups at-risk and people in
special situations is important to achieve the goal of universal access to high-
quality TB treatment and care. Context-specific and need-responsive actions,
such as developing specific policies at national and local levels, and innovative
service delivery mechanisms to avoid marginalizing those populations, would
be needed to address these issues.
Expected Result 2.4
Country-driven advocacy, communications and social mobilization (ACSM)
strategies developed and implemented
ACSM is an essential supporting element of TB control that can make a
measurable contribution to mobilizing and sustaining necessary political,
social and financial resources for TB control. ACSM can influence policy and
health services from the supply side, and behaviour and social change on the
demand side.  Furthermore, ACSM can assist in combating stigma and
discrimination, and in raising awareness and commitment in directing
attention to the often-neglected issue of access to TB services for poor and
vulnerable populations.
“Reaching the poor,
at-risk groups and
people in special
situations is
important to achieve
the goal of universal
access to
high-quality TB
treatment and care.”
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Social mobilization strategies that will lead to more meaningful participation
of affected communities in TB control can play an important role in achieving
actual and equitable access to TB services. Advocacy represents an important
means of engaging policy-makers, local government officials, public and
private health professionals, community leaders, patients and affected
communities in bringing about sustained behavioural and social changes
that will in turn contribute to TB control efforts. Because country settings
and needs are different, ACSM strategies need to be country-specific and
country-driven.  In the Western Pacific Region, ACSM strategies can make
a relevant contribution to more effectively reach the poor and vulnerable
populations and ensure equitable access to services by all TB patients.
Strategic Objective 3
To adapt DOTS to respond to MDR-TB and TB-HIV coinfection
The following table shows the four Expected Results under Objective 3 and
their corresponding indicators and targets, which are discussed in detail below.
Expected Result 3.1
Assessment of MDR-TB completed in targeted countries
Continuous monitoring of trends of anti-TB drug resistance, especially in
settings with high prevalence of MDR-TB, is essential to assess current
interventions and their impact on the TB epidemic.  Drug resistance surveys
(DRS) conducted between 1995 and 2004 provided useful information on
anti-TB drug resistance levels in some countries in the Region.  It will be useful
to repeat DRS in most settings to assess trends or to obtain data on resistance
patterns in the different categories of re-treatment cases.  In China, while
province-specific surveys will continue, a national DRS is planned that is
expected to provide a comprehensive picture of TB drug resistance situation
of the country.  In other countries, assessment of MDR using routine
surveillance data may be more efficient (e.g. countries with intermediate
DESCRIPTION INDICATORS AND TARGETS
Expected Result 3.1
Expected Result 3.2
Expected Result 3.3
Assessment of MDR-TB
completed in targeted countries
DOTS-Plus initiated or scaled up
in targeted countries
TB-HIV Framework for
collaboration developed and
implemented
All targeted countries (including 14
HBC and IBC) have assessed their
MDR-TB situation and trends
through drug resistance surveillance
At least 6 HBC initiated or scaled up
DOTS-Plus
At least 10% of failure cases tested by
DST
All targeted countries including 14
HBC and IBC are implementing TB-HIV
surveillance
At least 70% of TB patients are tested
for HIV in Category 1 and Category 2
countries/areas
At least 70% of newly diagnosed
patients with HIV tested for TB
Expected Result 3.4
Ensured access of TB patients to
HIV services (including
treatment, referral, VCT), and
similarly access to TB services for
persons with HIV/AIDS
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burden of TB, and the Pacific island countries and areas).  All countries that
plan to begin or are implementing DOTS-Plus programmes should use drug
resistance surveillance as a monitoring tool.
Expected Result 3.2
DOTS-Plus initiated or scaled up in targeted countries
Patients with identified MDR-TB should have access to quality-assured, second-
line anti-TB drugs.  Implementation of DOTS-Plus, designed to manage MDR-
TB under programme conditions, will be necessary in countries and areas
where MDR-TB is a serious threat to TB control. Several countries in the Region
are at varying stages of DOTS-Plus implementation.  Viet Nam is planning a
DOTS-Plus programme, while China and Mongolia are at the initial stages of
implementation.  The Philippines is scaling up its DOTS-Plus project.  Funding
of DOTS-Plus implementation in all these countries, with the exception of
Viet Nam, has been secured from the Global Fund to Fight AIDS, Malaria and
Tuberculosis (GFATM) for the next several years.
The long-term impact of DOTS-Plus depends on its expansion beyond pilot
projects.  More proactive scaling up of DOTS-Plus is necessary.  Countries will
need to address obstacles to scaling up, such as: (1) the need for wider access
to quality-assured culture and DST alongside the expansion of second-line
TB treatment; (2) lack of technical capacity for DOTS-Plus implementation;
and (3) weakness of health systems, including the lack of human resources to
deliver complex interventions in a DOTS-Plus programme.
Expected Result 3.3
TB-HIV Framework for collaboration developed and implemented
Collaboration between TB and HIV programmes is an essential first step to
initiate surveillance activities, which in turn is the starting point for intensified
case-finding and other collaborative TB-HIV activities. So far, ensuring
collaboration between the two programmes continues to be a challenge.
Only Cambodia has successfully expanded collaborative TB-HIV activities. In
view of the relatively low HIV prevalence, many countries in the Region may
not need to implement all collaborative TB-HIV interventions.  HIV prevalence
rates at the national and subnational levels should guide countries in
determining the types of collaborative TB-HIV activities to implementf.  TB-
HIV collaborative activities should be led by a national TB-HIV committee or a
working group that comprises the national TB and HIV/AIDS programmes
and substantial representation from partner agencies and communities
affected by the diseases.
Expected Result 3.4
Ensured access of TB patients to HIV services (including treatment, referral,
VCT), and similarly access to TB services for persons with HIV/AIDS
Early detection of HIV infection among TB patients or of TB among HIV-infected
patients followed by access to cotrimoxazole prophylaxis, ART and anti-TB
treatment is necessary to reduce mortality among TB-HIV coinfected patients.
f See Tuberculosis and HIV: A framework to address TB-HIV coinfection in the Western Pacific Region  p.22,
Box 6-Thresholds for Commencing Collaborative TB/HIV Activities
“HIV testing should
lead to care and
support, especially
treatment with ART,
as this is the most
effective way to
prevent mortality.”
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The timely provision of counselling and testing services by both TB and
HIV programmes is important.  For TB patients, identification of HIV status
is usually done in VCT centres.  However, in many countries in the Region,
VCT services are available only at a limited number of locations, thus
limiting access to these services.  One of the major constraints of
expanding VCT and promoting its utilization is the lack or insufficiency of
HIV/AIDS treatment,  care and support,  preventing people from
acknowledging and appreciating the benefits of VCT.  Countries should
take on the challenge of providing regular screening of persons infected
with HIV to be able to diagnose TB as early as possible and provide
treatment, care and support, including ART and anti-TB treatment, as this
is the most effective way to prevent TB mortality.
2.3 Cross-cutting and Health Systems
Components
Four cross-cutting issues have been identified that are related to
strengthening components of the health system relevant for TB control,
including: (1) human resources; (2) sufficient financing for TB control;
(3) operations research; and (4) monitoring and evaluation.  These
components do not fall uniquely under one of the three objectives, but
rather span the overall broad concerns of TB control, and for this reason,
have been labelled ‘cross-cutting’.  Strengthening these components
promotes practical ways to promote synergy between TB control and the
health system.  Strengthening these components in the context of TB
control is discussed in detail in this section.
2.3.1 Ensured availability of essential staff required for
TB control
The rapid scale-up of quality DOTS, particularly in settings with high rates
of HIV or MDR-TB, increases pressure on staff members in national TB
programmes.  Currently, many countries face problems related to quantity,
quality and distribution of staff.  This, of course, presents a huge challenge
as countries scale-up additional and more complex interventions for TB
control.  For the quality of DOTS to be improved and the twin threats of
TB-HIV coinfection and MDR-TB to be addressed, adequate numbers of
skilled and trained staff will need to be secured and mechanisms should
be developed to maintain and further strengthen their knowledge and
skills.
To ensure that there are sufficient numbers of quality staff in TB control,
political commitment is essential from the side of the NTP. However, this
only represents one component, since concerns about the quantity and
quality of staff is an issue, which is not specific to TB control programmes
and often dependent on factors outside the scope of the NTP.
Strengthening human resources requires action across all levels of
programmes, health systems, government departments, partnerships and
global stakeholders. Priority should be given to the development of
national and comprehensive human resource development plans that
cover improvements in educational policies, financial ceilings for
recruitment, and human resource planning including skills mix and
distribution, policies to improve staff recruitment, retention and
accountability, and budgets to ensure adequate remuneration.
“Strengthening
human resources
requires action
across all levels
of programmes,
health systems,
government
departments,
partnerships and
global stakeholders.”
Strategic Plan to Stop TB in the Western Pacific 2006–2010
24
2.3.2 Sufficient financing for TB control ensured
Expanding quality DOTS and addressing emerging issues, such as TB-HIV
coinfection and MDR-TB, require more costly interventions compared to
conventional DOTS.  Commitment to ensure adequate financing is needed
at all levels.  In view of the challenges that lie ahead, financing by governments
should be sustained at a minimum or, preferably, increased.  In addition,
sustaining partnerships and resource mobilization is essential as stated in
resolution WHA53.1 on Sustainable Financing for Tuberculosis Prevention and
Control24 as adopted by the Fifty-third World Health Assemblyg . At the global
level, the Stop TB Partnership will play an important role. At the regional level,
the role of the Interagency Coordination Committee (ICC) will be important
in sustaining partnerships. At the country level, various mechanisms of
partnerships should be sustained, including the Country Coordinating
Mechanism (CCM) established for the Global Fund to Fight AIDS, Tuberculosis
and Malaria.
2.3.3 Evidence-based policy and implementation
strategy development through operations
research
Operations research is a useful tool to evaluate and study the application of
various mechanisms, modalities and tools.  In view of the emerging challenges
and the increasing complexity of TB control, innovative approaches of
delivering or further improving TB care must be pursued. A careful assessment
through operational research of the benefits from the application of already
available but so far underused interventions or expected new tools will be
useful.  Various approaches, as well as implementation and operational issues
that are likely to impede progress, need to be carefully studied to develop
appropriate actions.
Practical Approach to Lung Health
Approaches to improve quality and access to DOTS include the Practical
Approach to Lung Health (PAL), which is a primary health care strategy for
the integrated management of respiratory conditions in patients aged 5 years
and over.  The aim of PAL is to improve the quality of care for every respiratory
patient and improve the efficiency of TB primary health care services. PAL has
the potential of increasing case detection and reducing the delay of care for
TB patients.  The Region may pilot this approach in some areas of China and
other selected countries.  PAL provides a practical example of how to improve
or strengthen TB case detection and the quality of TB diagnosis through the
integration of TB control activities within primary health care services.
Other operational research priorities
Other areas where operations research may benefit TB control programmes
include the diagnosis of childhood TB and extra-pulmonary TB;
improvement of information systems to secure the efficient transfer of
patient information between different geographical areas and various
g This World Health Assembly Resolution, which was adopted in May 2000, urges the Member States
to fulfil the commitments under the Amsterdam Declaration to Stop TB, including their commitment
to ensure the availability of resources to achieve the goals relevant to TB contained in the MDG.
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types of providers; further investigation of new diagnostic modalities, such
as those for sputum smear-negative TB; and application of new tools that
may become available within the next few years as a result of ongoing
global initiatives.
Addressing these operational research priorities will require strengthening
the capacity of the Region and countries to conduct operational research,
which will have positive effects on health systems capacity in general.
2.3.4 Enhanced surveillance and monitoring
and evaluation
Monitoring and evaluation (M&E) will be an integral part of TB work in all
areas over the next five years.  Current monitoring and evaluation systems
are designed to collect information on the intermediate targets of 2005, such
as the case detection rate, treatment success rate and DOTS coverage, as well
as other performance indicators for DOTS implementation. With the focus
expanding to other areas, the M&E system needs to adapt to monitor
programme performance better and to measure the achievement of the core
targets and the eventual goal.
Tracking programme performance or evaluating programme implementation
will continue to involve country programme reviews, at least twice for each
of the high burden countries over the next five years.  Surveillance activities
will be improved to feed into adjusting strategies, planning and
implementation.  Another crucial tool for M&E will be an enhanced TB
information system that can meet the information needs of the programme
in view of the new focus of the Strategic Plan to Stop TB in the Western Pacific
2006–2010. Good models of enhanced TB information systems exist in the
Region, such as the TB information system of China and the Republic of Korea.
Both systems are case-based and use the Internet for reporting, recording
and verification of TB cases, providing real-time information on individual cases.
Such systems need to be evaluated thoroughly.  Meanwhile, countries will
need to adopt a revised data collection tool to generate information on the
new concerns in the Strategic Plan.
The second area of focus of M&E is measuring the impact targets on
prevalence and mortality. Population-based surveys, such as prevalence
surveys of disease, can provide good estimates of prevalence and assess
prevalence trends in countries that had prior surveys conducted, including
China, the Philippines and the Republic of Korea.  Technical and financial
support to countries will be crucial as prevalence surveys are technically
demanding and resource-intensive. Measuring mortality accurately remains
a challenge because of limitations of current vital registration systems in
countries with a high burden of TB.  Efforts will need to be pursued to improve
the quality of information on mortality.
“The M&E system
needs to adapt in
order to monitor
the programme
performance better
and to measure
the achievement
of the core targets
and the eventual
goal.”

3.1 Resource needs of the Region
The total investment required to implement planned TB control activities in
the Region is estimated at US$ 2.2 billion over five years from 2006 to 2010
(see Figure 7 for detailed breakdown of resource needs). This total includes all
required investments for TB control in the Region, which include contributions
by governments, partners, technical agencies and private entities. This figure
is based on estimates provided by the Global Plan to Stop TB 2006–201525, in
which cost estimates were generated through detailed and systematic analysis
of existing data and projections on cost and outcomes for each of the regions.
There are four main areas for which required resources were estimated:
(1) basic delivery of DOTS; (2) improving the quality of DOTS and new
approaches for DOTS delivery; (3) activities to address MDR-TB; and (4) TB-HIV
collaborative activities.
About US$ 1.45 billion will be needed to sustain basic DOTS delivery.  This
includes the basic TB control activities that the national TB programmes are
already implementing. The cost was estimated based on financial data
submitted by NTP in 2005 that included cost components of existing NTP
budgets and the use of general health system resources in basic DOTS delivery.
After adjusting for inflation, it is assumed that the resource needs by the TB
programme to deliver basic DOTS will be the same in the next five years.
Improving the quality of DOTS and implementing new approaches have been
costed separately.  This main cost area includes enhancing laboratory capacity
and quality, and implementing new approaches, such as PPMD, community
care, advocacy, communications and social mobilization, and PAL, which will
be implemented in several areas in the Region.
The estimated cost of addressing MDR-TB in the next five years
(US$ 210 million) appears to be small in comparison to the total resource
needs. Activities will be started in a few areas and gradually expanded.
Progressive implementation is justified because of the current limited capacity
in countries and the complex preparation needed for implementing DOTS-
Plus.  Thus, once at the scale-up phase, the required resources will increase
significantly over time and will continue to do so beyond 2010.
Section 3
Resource Needs
and Gaps
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The required resources for TB-HIV collaborative activities will substantially
increase in the next several years.  The Region will intensify efforts to get
collaborative activities started in China, Malaysia, Papua New Guinea and
Viet Nam, and further scaled up in Cambodia.  About US$ 64 million will be
needed to implement necessary activities outlined in the regional framework
for addressing TB-HIV coinfection. As a full range of activities will be needed
in only a few countries that have a significant TB-HIV problem, the proportion
of the estimated cost for TB-HIV activities is small compared to the total
resource needs of the Region.  In most countries, joint TB-HIV surveillance will
be the essential activity.
In summary, over the next five years, the Region will require
US$ 400 million to US$ 500 million per year for TB control.  The cost increases
over time within the next five years because of the progressive scale-up of
activities to address MDR-TB.
Section 3.2 Funding Gap
There are three main sources of funding for TB control, namely domestic
financing (both local and national budgets), funding from the Global Fund
to Fight AIDS, Tuberculosis and Malaria (GFATM), and funding from other
partners.  Total projected available domestic financing for TB is around
US$ 1.26 billion, which was estimated based on the financing data
submitted in 2005 by the seven countries with a high burden of TB.
Additional US$ 130 million is expected from the GFATM based on the five-
year budgets of the approved grants in all previous rounds for five
countries with a high burden of TB and the Pacific.
With the assumption that domestic financing will be sustained until 2010
and that no major reduction will be made in the budgets for proposals
already approved by GFATM, the funding gap is estimated to be around
US$ 637 million over five years. The gap increases over time because of
increasing resource needs while financing remains constant, and grants
from future GFATM rounds have not been projected (see Figure 8).
Nonetheless, future GFATM grants alone are not expected to be able to
bridge the gap.  Closing the funding gap will be crucial as a large
FIGURE 7. ESTIMATED RESOURCE NEEDS FOR 2006–2010
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proportion of this will be needed to finance the scale-up of DOTS-Plus
and TB-HIV and for new approaches to improve the quality of DOTS
implementation.  While there is no existing funding for activities in these
areas, the scale-up of these activities is critical to achieving the 2010
regional goals.
FIGURE 8. ESTIMATED FINANCING GAP FOR 2006-2010

Section 4
Risk Assessment
There are a number of risk factors that may impede progress towards achieving
the objectives laid out in this Strategic Plan. These factors exist at different
levels and are of different magnitudes.  They reflect the fact that TB control
services are delivered in the context of the overall political, cultural, health,
economic and social environment.
The risks factors are most relevant to countries with a high burden of TB in
the Region.
(1) Decentralization of TB control activities to lower levels
Reforms in the overall health sector tend to decentralize a major part of the
responsibilities of delivering health services to lower level governance.  This
does not necessarily lead to more effective delivery of TB services and better
outcomes for TB control.  The increased responsibilities that come with
decentralization are quite often unaccompanied by systematic capacity
strengthening.  The lack of capacity at lower levels to absorb more intensified
actions required for TB control in the next five years poses a serious threat to
achieving the regional goal for TB.  A comprehensive plan for strengthening
lower-level capacity to deliver health care and increasing the involvement of
communities and other non-NTP health providers will be important to
mitigate the risks.
(2) Loss or decline in commitment to TB control
As has been shown in the last several years, political will at all levels of health
governance makes a huge difference in ensuring successful TB control.  At
the lower levels (i.e., provincial or district), TB will increasingly compete
with other priorities, not only with other health priorities, but also with
other projects that are perceived to generate greater political mileage
(e.g. infrastructure projects).  With TB services increasingly being decentralized
in most countries with a high burden of TB in the Region, there is a risk for a
decline in commitment for TB control.  TB programmes must not fail to sustain
political commitment, especially at the lower levels of governance through
effective advocacy and by ensuring optimum programme performance.
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(3) Social and economic conditions
Progress in TB control is very much dependent on the social and economic
condition of the country.  If widespread poverty and the resultant social
problems continue to persist in many countries in the Region those will
present a huge barrier to achieving meaningful progress in TB control. In
countries experiencing rapid economic development, new problems arise
that are associated with rising vulnerabilities of the population related to the
increasing pace of urbanization and mobility.  These problems need serious
attention to reduce people’s vulnerability to TB and to ensure that TB services
are accessible to all patients, especially migrant or floating populations.
(4) Shifting TB control responsibilities outside the public
sector
A new focus on the involvement of the private sector and civil society may
result in a less prominent role of the government sector in TB control. There is
a need to strongly advocate for increased resources to continue to strengthen
the public sector as a core condition for involving other sectors. If health
systems, including health infrastructure and human resource capacity,
continue to be weak, expansion of services, intensified implementation of
activities, particularly with the necessary focus on quality improvement, will
be challenged.
(5) Reduced funding levels
With the implementation and scale-up of the new strategies, TB control in
the next five years will require increased investments.  Without additional
resources, expansion and scale-up of strategies will be seriously compromised.
It will be crucial to continue stressing the need for high-quality basic DOTS
functions as a prerequisite to the expansion to other components, while raising
the additional resources needed for expanding and scaling up of other
components of the Strategic Plan and promoting efficiency in the use of
resources for TB control.
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ANNEX 1. Hierarchy of Desired Outcomes of the Strategic Plan
to Stop TB in the Western Pacific 2006–2010
VISION
GOAL
Elimination of TB as a public health problem
To reduce prevalence and mortality from all forms of TB by one half
by 2010 relative to 2000, contributing to the achievement of the
Millennium Development Goals
Objective 1. To sustain and optimize the quality of DOTS and go beyond the ‘70/85’ targets
Target 1. Beyond 70% case detection rate (core target)
Target 2. Beyond 85% cure rate
Expected Results:
1.1. Country capacity and quality of diagnosis for TB assured
1.2. Uninterrupted supply of quality-assured anti-TB drugs at all DOTS units
1.3. Enhanced case management for all registered TB cases, including smear-negative TB.
Objective 2. To ensure equitable access to high-quality TB care for all people with TB
Target 3. At least 90% of facilities including private or general hospitals providing or making referrals for
DOTS (core target)
Expected Results:
2.1. Improved TB case management in non-NTP TB facilities
2.2. Adoption of the International Standards of Tuberculosis Care (ISTC) and the Patients’ Charter for
Tuberculosis Care (PCTC)
2.3. Increased utilization of TB services by poor and vulnerable populations
2.4. Country-driven advocacy, communications and social mobilization (ACSM) strategies developed
and implemented.
Objective 3. To adapt DOTS to respond to MDR-TB and TB-HIV coinfection
Target 4. At least 90% of identified MDR-TB cases by DST are provided with quality-assured, second-line
treatment (core target)
Target 5. At least 90% of identified HIV-infected TB patients eligible for ART that are provided with ART
(core target)
Expected results:
3.1. Assessment of MDR-TB completed in targeted countries
3.2. DOTS-Plus initiated or scaled up in targeted countries
3.3. TB-HIV Framework for collaboration developed and implemented
3.4. Ensured access of TB patients to HIV services (including treatment, referral, VCT), and similarly
access to TB services for persons with HIV/AIDS.
STRATEGIC OBJECTIVES AND EXPECTED RESULTS
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Notified TB cases
Population
thousands
DOTS
coverage
%
New and relapse
(WHO total)
New pulmonary Estimated incidence Case detection rate
Number Rate
SS+ SS- / unk.
number
all forms
number
SS+
number
new and
relapse %
new SS+
%
American Samoa
Australia
Brunei Darussalam
Cambodia
China
Cook Islands
Fiji
French Polynesia
Guam
Hong Kong (China)
Japan
Kiribati
Lao PDR
Macao (China)
Malaysia
Marshall Islands
Micronesia
Mongolia
Nauru
New Caledonia
New Zealand
Niue
Northern Mariana Islands
Palau
Papua New Guinea
Philippines
Rep. Korea
Samoa
Singapore
Solomon Islands
Tokelau
Tonga
Tuvalu
Vanuatu
Viet Nam
Wallis & Futuna
Western Pacific Region
63
19 942
366
13 798
1 307 989
18
841
253
167
6963
127 923
97
5792
457
24 894
60
110
2614
13
233
3989
1
79
20
5772
81 617
47 645
184
4273
466
1
102
10
207
83 123
15
1 740 099
100
63
100
100
96
98
100
100
100
100
71
100
98
100
100
100
90
100
100
100
100
100
95
47
100
100
100
100
100
100
94
5
1059
176
30 838
790 603
1
134
60
51
6143
29 736
310
3173
323
14 986
119
118
4570
61
373
0
53
5
12 743
130 530
34 671
1 516
340
115
98 389
1 161 201
8
5
48
223
60
6
16
24
31
88
23
318
55
71
60
199
108
175
26
9
0
67
25
221
160
73
35
73
55
118
67
2
285
115
18 978
384 886
1
62
30
22
1 694
10 471
142
2 241
128
7843
39
35
1808
15
112
0
14
5
1896
78 163
11 501
506
152
59
58 389
579 594
3
1
31
138
29
6
7
12
13
24
8
146
39
28
32
65
32
69
6
3
0
18
25
33
96
24
12
33
28
70
33
1
337
15
5800
284 433
0
38
12
9
3073
12 384
59
472
129
5136
38
51
866
14
86
0
34
0
5234
47 937
16 446
660
107
32
17 106
400 509
Number Rate
Incidence and case detection rates
2003 ss+ cohort
Cure/success
Cured
%
Success
%
HIV-TB
prevalence
in adult
incident
TB cases (%)
MDR-TB
Re-treat
DST
number
Re-treat
MDR
number
Prevalence
2000
All forms
rate
2004
All forms
rate
All forms
change*
Mortality
2000
All forms
rate
2004
All forms
rate
All forms
change*
18
1132
197
70 370
1 324 633
5
239
72
98
5223
37 814
57
9019
373
25 527
35
65
5018
4
137
424
0
46
12
13 455
239 459
43 029
52
1691
274
0
29
3
122
146 695
4
1 925 332
8
507
89
31 118
595 381
2
107
32
44
2349
17 006
26
4056
167
11 449
16
29
2257
2
62
191
0
21
5
6025
107 738
19 339
24
757
123
0
13
1
55
65 745
2
864 745
28
94
89
44
60
19
56
84
52
118
79
540
35
87
59
338
183
91
45
88
0
114
43
95
55
81
90
124
94
67
60
25
56
129
61
65
43
58
93
50
72
62
550
55
76
69
246
120
80
24
59
0
67
95
31
73
59
67
123
107
89
67
100
17
45
90
91
86
96
73
50
74
70
85
69
90
27
84
75
75
80
41
81
81
68
70
90
87
100
82
60
93
94
86
83
96
78
76
88
79
88
72
90
92
87
75
36
75
80
58
88
82
77
87
75
92
91
0.1
3.9
0.1
13
0.9
0.1
1.0
2.3
2.6
0.4
0.6
0.03
0.5
1.0
2.5
0.03
0.03
0.4
0.1
1.5
2.1
0.1
0.1
0.1
3.7
0.1
0.9
0.4
5.2
0.1
0.1
0.1
0.1
0.1
3.0
0.1
1.4
0
5
0
0
1
11
0
513
0
0
22
0
8
4
40
10
0
0
0
0
278
117
1 009
0
2
0
0
1
0
0
19
0
0
2
0
2
1
14
0
0
0
0
0
0
39
0
80
62
6
56
789
271
57
50
41
113
86
46
75
357
86
139
87
94
285
52
105
11
68
75
149
628
554
139
43
46
82
68
44
68
94
251
68
261
49
6
63
709
221
51
41
56
91
77
39
59
318
90
133
59
59
209
35
117
11
57
68
91
448
463
125
43
41
59
57
42
57
64
232
28
216
79%
97%
112%
90%
82%
90%
82%
137%
81%
89%
86%
79%
89%
105%
96%
68%
63%
73%
67%
112%
100%
84%
91%
61%
71%
84%
90%
99%
89%
72%
84%
96%
84%
68%
92%
42%
83%
7
1
4
105
20
6
6
5
12
7
4
5
28
7
17
10
11
36
4
12
1
7
5
11
56
58
11
5
5
10
7
4
6
8
24
7
20
5
1
5
94
17
5
5
5
10
6
4
4
25
10
16
4
4
24
4
12
1
6
8
7
42
48
10
5
4
4
6
5
5
5
22
2
18
81%
97%
125%
90%
84%
83%
83%
93%
86%
89%
87%
79%
90%
134%
97%
43%
40%
67%
103%
98%
100%
84%
144%
64%
75%
83%
91%
97%
89%
45%
84%
125%
84%
66%
94%
30%
88%
ss+ indicates sputum smear-positive; ss-, sputum smear-negative; unk., sputum smear result unknown; re-treat., re-treatment; pulm.lab.
* 2004 value / 2000 value, expressed as a percentage.
ANNEX 2.  Data on Main Tuberculosis Indicators in the Western Pacific Region, 2004
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TB Resolution during the Fiftieth Session of the Regional Committee
WPR/RC50.R5
TUBERCULOSIS PREVENTION AND CONTROL
The Regional Committee,
Noting that tuberculosis kills more youths and adults than any other infectious disease in
the world;
Noting further that tuberculosis is re-emerging as a major public health problem in the
Region, as demonstrated by the steady increase in notified tuberculosis cases during the
last decade and the fact that 29% of global tuberculosis cases are found in the Western
Pacific Region;
Noting that political commitment has not yet been translated into increased resources for
tuberculosis control;
Recognizing that tuberculosis is also a serious public health problem in newly industrialized
and developed countries;
Acknowledging that the directly-observed treatment, short course (DOTS) strategy is the
most cost-effective way of controlling tuberculosis, saving the lives of patients and
preventing the emergence of drug resistance;
Expressing concern that only 46% of notified tuberculosis cases in the Region were enrolled
in DOTS programmes in 1998;
Expressing further concern at the negative impact of HIV on tuberculosis in some countries
of the Region;
DECLARES a ‘Tuberculosis crisis’ in the Western Pacific Region;
URGES Member States:
(1) to give high priority, and to allocate sufficient resources, to strengthening tuberculosis
control;
(2) to aim to increase the percentage of tuberculosis patients enrolled in DOTS programmes
so that the regional targets of 60% of notified cases to be treated by DOTS by 2001 and
100% by 2005 are achieved;
(3) to achieve and maintain a cure rate of at least 85% by ensuring high-quality DOTS
implementation, as a minimum;
(4) to implement surveillance for drug-resistant tuberculosis by 2001;
(5) to establish regular surveillance and reporting of the impact of HIV on tuberculosis by
2001, if this is appropriate;
REQUESTS the Regional Director:
(1) to give tuberculosis control high priority and to make “Stop TB in the Western Pacific
Region” a special project of the Western Pacific Regional Office;
ANNEX 3. Key Resolutions by the WHO Regional Committee on
Tuberculosis Control in the Western Pacific Region
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(2) to take all possible steps to raise awareness of the tuberculosis problem based on
evidence from epidemiological studies and cost-benefit and socioeconomic analysis
and to take all necessary measures to influence leading political figures to translate
political commitment into increased financial resources;
(3) to strengthen technical collaboration with Member States in order to introduce and
expand the DOTS strategy in the Region in the context of health sector reform and
poverty alleviation;
(4) to strengthen partnerships with other technical and funding agencies in the Western
Pacific Region;
(5) to report annually in progress in tuberculosis control to the Regional Committee.
17 September 1999
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TB Resolution during the Fifty-first Session of the Regional Committee
WPR/RC51.R4
TUBERCULOSIS PREVENTION AND CONTROL
The Regional Committee,
Concerned that tuberculosis is a major cause of premature death and human suffering in
the Western Pacific Region;
Recognizing that tuberculosis is strongly associated with social and economic inequalities;
Recognizing further that the regional burden of tuberculosis is also a major impediment to
socio-economic development, especially in developing countries, where most cases and
deaths occur among the poorest and most vulnerable;
Noting that an uninterrupted drug supply has not yet been secured in many of the countries
in the Region with a high tuberculosis burden;
Expressing concern that only 44% of the total estimated new smear-positive cases in the
Region were detected in 1998;
Expressing further concern at the emergence, and potential for expansion, of multidrug-
resistant tuberculosis in the Region;
Acknowledging that the WHO recommended tuberculosis strategy, directly observed
treatment, short-course (DOTS), is a very cost-effective health intervention that has already
achieved high treatment success rates in the Region;
Acknowledging further that the effective implementation of DOTS programmes can reduce
the prevalence and mortality of tuberculosis in the Region by half by 2010;
Welcoming, in response to resolution WPR/RC50.R5, the establishment of the Stop TB special
project in collaboration with Member States and the international community;
Welcoming further the holding of the first tuberculosis Technical Advisory Group meeting
and the establishment of a Pacific Stop TB Initiative;
ENDORSES the ‘Regional strategic plan to Stop TB in the Western Pacific’, which was finalized
at the first meeting of the tuberculosis Technical Advisory Group;
URGES Member States:
(1) to develop and implement five year (2001-2005) Stop TB national plans to achieve the
regional objective of reducing prevalence and mortality of tuberculosis by half by 2010;
(2) to increase the case detection rate to 70% of estimated new smear-positive cases by
2005;
(3) to increase the enrolment rate in DOTS programmes for new detected smear-positive
tuberculosis cases to 100% by 2005;
(4) to establish or strengthen partnerships at the country level through the information
or enhancement of national Interagency Coordinating Committees;
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(5) to strengthen health systems to effectively implement Stop TB national plans;
(6) to include case detection, DOTS implementation and treatment success rates in the
performance indicators for overall health system development;
REQUESTS the Regional Director:
(1) to strengthen technical support to Member States to develop and implement Stop TB
national plans with the framework of health system development and the healthy
settings approach;
(2) in partnership with Member States and partner agencies to improve access to
anti-tuberculosis drugs, paying particular attention to disadvantaged groups, including
people living in poverty;
(3) to enhance partnerships to support the Stop TB special project in the Region in
collaboration with the global Stop TB partners;
(4) to enhance technical collaboration with Member States to implement surveillance for
drug-resistant tuberculosis and to establish regular surveillance of HIV-associated
tuberculosis;
(5) to support Member States, particularly those with a high burden of tuberculosis, to
conduct prevalence surveys in order to evaluate progress in tuberculosis control.
22 September 2000
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TB Resolution during the Fifty-seventh Session of the Regional Committee
WPR/RC57.R6
TUBERCULOSIS PREVENTION AND CONTROL
The Regional Committee,
Acknowledging indications from early reports that the Western Pacific Region has met the
2005 targets for tuberculosis (TB) control, which include regionwide directly observed
treatment, short-course (DOTS) coverage, detection of 70% of the estimated TB cases, and
successful treatment of at least 85% of such cases;
Appreciating that successful implementation of the Stop TB Regional Strategic 2000-2005
has facilitated achievements of these targets;
Recognizing that the achievement of the 2005 regional TB control targets is only an
intermediate step towards achieving the regional goals of reducing by one-half the
prevalence and mortality due to TB by 2010;
Noting that the current 3% annual decline in TB prevalence and mortality would have to
increase to an 8% annual decline, based on WHO modelling, for the Region to achieve the
2010 regional goal;
Expressing concerns over issues of the quality of DOTS implementation in some parts of
the Region, the need to work towards ensuring equitable access to TB care, and the necessity
of engaging all health care providers in TB control;
Expressing further concern at the threats of multidrug-resistant TB and the TB-HIV
coinfection, as well as extensive drug-resistant TB (XDR-TB) that could undermine the gains
achieved so far in TB control;
Noting that the TB Technical Advisory Group in its meeting in Busan, Republic of Korea, in
March 2006 supported the Strategic Plan to Stop TB in the Western Pacific 2006-2010 as
technically sound,1
1 RENEWS the commitment to the regional goal of reducing TB prevalence and mortality
by one-half by 2010, thereby contributing to the TB-related United Nations Millennium
Development Goals;
2 ENDORSES the Strategic Plan to Stop TB in the Western Pacific 2006-2010, aimed at
providing guidance to countries and areas in the Region to address the challenges
and sustain the momentum towards the 2010 regional goals;
3 URGES Member States:
(1) to further strengthen the political commitment for TB control, to strengthen health
systems and to work to ensure the availability of the human resources required for
TB control and to take an active role in ensuring sustainable financing for TB control;
(2) to develop or finalize and implement national TB control plans guided by the
Strategic Plan to Stop TB in the Western Pacific 2006-2010, including monitoring
and evaluation of results based on agreed indicators and targets;
1 Annex to Document WPR/RC57/8.
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(3) to implement measures in countries and areas in the Region that
have not yet achieved the regional TB control targets for 2005: 100%
of the population with access to DOTS; 70% of estimated TB cases
are detected; and 85% of the detected cases are successfully treated;
4. REQUESTS the Regional Director:
(1) to work closely with Member States, partner organizations and
relevant stakeholders to further strengthen their commitment to TB
control to address primarily the need to sustain financing and to work
towards ensuring adequate human resource capacity;
(2) to provide effective support to Member States in developing and
implementing five-year national plans for 2006-2010, including
monitoring the four core targets that will address the specific
challenges to achieve the regional goal by 2010 and the Millennium
Development Goals by 2015;
 (3) to support Member States, specifically those that have not achieved
the 2005 intermediate TB control targets, in further strengthening
their efforts.
21 September 2006
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